Fate Therapeutics (FATE)
(Delayed Data from NSDQ)
$5.41 USD
-0.03 (-0.55%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $5.41 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Company Summary
Fate Therapeutics is a clinical-stage biopharmaceutical company that is focused on the development of programmed cellular immunotherapies for cancer and immune disorders.
Fate Therapeutics created and engineered human induced pluripotent stem cells (“iPSCs”) to incorporate novel synthetic controls of cell function to generate better cell therapies. The company is advancing a cell therapy pipeline comprised of off-the-shelf, multiplexed-engineered, iPSC-derived natural killer (“NK”) and T-cell product candidates that are selectively designed, incorporate novel synthetic controls of cell function and are intended to deliver multiple mechanisms of therapeutic importance to patients for ...
Company Summary
Fate Therapeutics is a clinical-stage biopharmaceutical company that is focused on the development of programmed cellular immunotherapies for cancer and immune disorders.
Fate Therapeutics created and engineered human induced pluripotent stem cells (“iPSCs”) to incorporate novel synthetic controls of cell function to generate better cell therapies. The company is advancing a cell therapy pipeline comprised of off-the-shelf, multiplexed-engineered, iPSC-derived natural killer (“NK”) and T-cell product candidates that are selectively designed, incorporate novel synthetic controls of cell function and are intended to deliver multiple mechanisms of therapeutic importance to patients for the treatment of cancer and autoimmune disease. Fate Therapeutics has a deep pipeline of iPSC-derived, chimeric antigen receptor (“CAR”)-targeted NK and T-cell product candidates currently under development with multiple clinical trials ongoing.
In September 2018, Fate Therapeutics entered into a collaboration and option agreement with Ono Pharmaceutical Co., Ltd, whereby it is researching and developing iPSC-derived CAR NK and CAR T-cell product candidates for the treatment of solid tumors.
In January 2023, Fate Therapeutics announced the termination of its partnership with Janssen. Both companies entered into an agreement in April 2020 to collaborate on the development of iPSC-derived CAR NK and CAR T-cell product candidates for the treatment of cancer. As a result, during the first quarter of 2023, Fate Therapeutics and Janssen closed all collaboration activities, including discontinuing the development of all collaboration products, at Janssen's expense.
Fate Therapeutics has completed a strategic review of its NK cell programs and elected to advance its most innovative and differentiated product candidates. As a result of this program prioritization, as well as the termination of the Janssen collaboration, Fate Therapeutics discontinued the development of its FT516, FT596, FT538 and FT536 NK cell programs and reduced its workforce to approximately 220 employees.
The company generated collaboration revenues of $63.5 million in 2023, down from $96.3 million in 2022.
General Information
Fate Therapeutics, Inc
12278 SCRIPPS SUMMIT DRIVE
SAN DIEGO, CA 92131
Phone: 858-875-1800
Fax: NA
Web: http://www.fatetherapeutics.com
Email: christina.tartaglia@sternir.com
Industry | Medical - Biomedical and Genetics |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 6/30/2024 |
Exp Earnings Date | 8/13/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | -0.47 |
Current Year EPS Consensus Estimate | -1.90 |
Estimated Long-Term EPS Growth Rate | 24.70 |
Exp Earnings Date | 8/13/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 5.44 |
52 Week High | 8.83 |
52 Week Low | 1.63 |
Beta | 1.90 |
20 Day Moving Average | 1,966,078.62 |
Target Price Consensus | 6.93 |
4 Week | 65.85 |
12 Week | 33.99 |
YTD | 45.46 |
4 Week | 65.90 |
12 Week | 25.86 |
YTD | 27.09 |
Shares Outstanding (millions) | 113.83 |
Market Capitalization (millions) | 619.25 |
Short Ratio | NA |
Last Split Date | NA |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | NA |
Change in Payout Ratio | NA |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | NA |
Trailing 12 Months | NA |
PEG Ratio | NA |
vs. Previous Year | -147.37% |
vs. Previous Quarter | -4.44% |
vs. Previous Year | -96.74% |
vs. Previous Quarter | 14.86% |
Price/Book | 1.45 |
Price/Cash Flow | NA |
Price / Sales | 95.59 |
6/30/24 | NA |
3/31/24 | -46.49 |
12/31/23 | -38.17 |
6/30/24 | NA |
3/31/24 | -34.48 |
12/31/23 | -28.42 |
6/30/24 | NA |
3/31/24 | 8.69 |
12/31/23 | 8.48 |
6/30/24 | NA |
3/31/24 | 8.69 |
12/31/23 | 8.48 |
6/30/24 | NA |
3/31/24 | -2,933.79 |
12/31/23 | -253.30 |
6/30/24 | NA |
3/31/24 | -2,933.79 |
12/31/23 | -253.30 |
6/30/24 | NA |
3/31/24 | -2,933.79 |
12/31/23 | -253.30 |
6/30/24 | NA |
3/31/24 | 3.74 |
12/31/23 | 3.74 |
6/30/24 | NA |
3/31/24 | NA |
12/31/23 | NA |
6/30/24 | NA |
3/31/24 | 0.00 |
12/31/23 | 0.00 |
6/30/24 | NA |
3/31/24 | 0.00 |
12/31/23 | 0.00 |